Bioporto Diagnostics A/S
Public limited companyCVR 18645882HellerupActive
Bioporto Diagnostics A/S is a public limited company, based in Hellerup, active in research and experimental development on natural sciences and engineering, founded in 1995. Equity was negative at the end of 2025 (−DKK 837.6m). The company made a loss in both 2024 and 2025, most recently DKK 81.4m. With 28 employees, the company is about 6 times larger than the industry median.
Key figures · financial year 2025
RevenueDKK 40.3m+11.2% vs. 2024
Net profit−DKK 81.4m+26.6% vs. 2024
Equity−DKK 837.6m−10.8% vs. 2024
Employees28latest month from CVR
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- Revenue rose 11% (2024 → 2025), to DKK 40.3m.
- The loss got smaller: from DKK 110.9m to DKK 81.4m (2024 → 2025).
Employees
- 1 more employees than a year earlier: 28 (08/2026) against 27 (08/2025).
Management and owners, last 24 months
- New in management: Carsten Buhl (board member, 01/09/2025), Carsten Buhl (ceo, 01/09/2025) and Klaus Juhl Wulff (board member, 01/04/2026) (+1).
- Stepped down: Nis Glavind Kruse (board member, 01/02/2025), Peter Mørch Eriksen (ceo, 01/09/2025) and Peter Mørch Eriksen (board member, 01/09/2025) (+1).
Registrations, last 24 months
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2020–2025 · amounts in DKK thousandEquity and net profit
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|---|---|
| Revenue | 23,204 | 24,254 | 28,969 | 30,958 | 36,243 | 40,287 | +11.2% |
| Gross profit | −10,556 | −15,175 | −13,193 | −4,436 | −8,337 | −18,866 | −126.3% |
| Operating profit (EBIT) | −41,882 | −47,502 | −67,347 | −58,514 | −61,316 | −68,946 | −12.4% |
| Profit before tax | −46,843 | −60,236 | −87,270 | −108,979 | −116,408 | −86,898 | +25.4% |
| Net profit | −42,628 | −54,123 | −81,772 | −104,753 | −110,908 | −81,398 | +26.6% |
| Total assets | 22,019 | 22,985 | 12,785 | 14,396 | 20,389 | 24,807 | +21.7% |
| Equity | −404,626 | −458,749 | −540,521 | −645,274 | −756,183 | −837,581 | −10.8% |
| Liabilities | 426,645 | 481,734 | 553,306 | 659,670 | 776,572 | 862,387 | +11.1% |
| Cash and cash equivalents | 7,660 | 9,268 | 3,765 | 5,557 | 2,523 | 2,054 | −18.6% |
| Average number of employees | 16 | 15 | 20 | 21 | 22 | 26 | +18.2% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 837.6m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 6 years in a row
Net result has been negative in 2020–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
6 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 09/04/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 17/06/2025 | The company | PDF not statedXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 27/06/2024 | The company | PDF not statedXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 30/06/2023 | The company | PDF not statedXBRL |
| 2021 | 01/01/2021 – 31/12/2021 | 30/06/2022 | The company | PDF not statedXBRL |
| 2020 | 01/01/2020 – 31/12/2020 | 30/06/2021 | The company | PDF not statedXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Gross profit−DKK 18.9mNo. 405 of 421
Better than 4% of the companies in the industry
Equity−DKK 837.6mNo. 430 of 431
Better than 0% of the companies in the industry
Number of employees28No. 75 of 431
Better than 83% of the companies in the industry
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with 20–49 employees9,922 companies in the comparison | No. 9,863of 9,892 Better than 0% | No. 9,920of 9,922 Better than 0% |
| Same industry and 20–49 employees64 companies in the comparison | No. 54of 62 Better than 13% | No. 63of 64 Better than 2% |
| Companies that are at least 30 years old10,276 companies in the comparison | No. 10,139of 10,152 Better than 0% | No. 10,274of 10,275 Better than 0% |
| All companies of type A/S18,025 companies in the comparison | No. 17,729of 17,786 Better than 0% | No. 18,021of 18,024 Better than 0% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineeringGross profit
- Bioporto Diagnostics A/S−DKK 18.9m
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
Net profit
- Bioporto Diagnostics A/S−DKK 81.4m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
Equity
- Bioporto Diagnostics A/S−DKK 837.6m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
Employees
- Bioporto Diagnostics A/S28
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership RegisterOwners
Bioporto Diagnostics A/S
Management
4 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Carsten Buhl | CEO | 01/09/2025 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Gry Louise Husby Larsen | Chair of the board | 22/01/2024 |
| Carsten Buhl | Board member | 01/09/2025 |
| Klaus Juhl Wulff | Board member | 01/04/2026 |
- Founders
- Asx 9667 ApS
Former management (33)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Steen Schierbeck | Director | 01/07/1995 | 10/01/1996 |
| Torsten Bjørn | Director | 10/01/1996 | 16/07/1998 |
| Claus Henrik Jepsen | Board member | 28/05/2002 | 27/04/2005 |
| Henrik Lasse Lindblad | Board member | 28/05/2002 | 26/10/2005 |
| Henrik Lasse Lindblad | Director | 28/05/2002 | 01/04/2005 |
| Christian Foldberg Rovsing | Chair of the board | 28/05/2002 | 24/05/2007 |
| Christian Foldberg Rovsing | Director | 28/05/2002 | 28/05/2002 |
| Eske Rygaard-Hjalsted | CEO | 01/04/2005 | 30/03/2006 |
| Lars Heslet | Board member | 27/04/2005 | 27/06/2007 |
| Thea Olesen | Board member | 26/10/2005 | 18/07/2013 |
| Lars Otto Uttenthal | Board member | 26/10/2005 | 30/05/2013 |
| Thea Olesen | CEO | 30/03/2006 | 18/07/2013 |
| Knud Carsten Bernhard Lønfeldt | Chair of the board | 18/07/2007 | 15/04/2013 |
| Thomas Magnussen | Chair of the board | 15/04/2013 | 12/01/2022 |
| Torben Arnth Nielsen | Board member | 30/05/2013 | 17/06/2021 |
| Peter Mørch Eriksen | Board member | 18/07/2013 | 12/01/2022 |
| Peter Mørch Eriksen | CEO | 18/07/2013 | 12/01/2022 |
| Otto Christian Aagaard Rasmussen | Chief financial officer | 01/01/2014 | 16/01/2015 |
| Ole Larsen | Board member | 29/05/2019 | 17/06/2021 |
| Henrik Clausen | Board member | 17/06/2021 | 11/01/2022 |
| Henrik Clausen | Deputy chair | 12/01/2022 | 30/06/2022 |
| Anthony Paul Pare | Board member | 12/01/2022 | 09/01/2024 |
| Anthony Paul Pare | CEO | 12/01/2022 | 09/01/2024 |
| Neil Allan Goldman | Chair of the board | 12/01/2022 | 15/10/2023 |
| John Patrick McDonough | Board member | 30/06/2022 | 09/11/2022 |
| Jan Leth Christensen | Board member | 09/11/2022 | 14/10/2023 |
| Peter Mørch Eriksen | Board member | 09/11/2022 | 04/12/2023 |
| Jan Leth Christensen | Chair of the board | 15/10/2023 | 04/12/2023 |
| Nis Glavind Kruse | Board member | 05/12/2023 | 01/02/2025 |
| Peter Mørch Eriksen | Chair of the board | 05/12/2023 | 21/01/2024 |
| Peter Mørch Eriksen | CEO | 09/01/2024 | 01/09/2025 |
| Peter Mørch Eriksen | Board member | 22/01/2024 | 01/09/2025 |
| Niels Jørgen Høy Nielsen | Board member | 01/02/2025 | 01/04/2026 |
Signing rule: Selskabet tegnes af den samlede bestyrelse, af bestyrelsesformanden sammen med en direktør eller af to direktionsmedlemmer i forening.
Address and production units
1 active production unitsTuborg Havnevej 15
2900 Hellerup
Gentofte Municipality · Postcode 2900
Other companies at the address (1)
- Bioporto A/SResearch and experimental development on natural sciences and engineering
| Production unit | Address | Employees | P number |
|---|---|---|---|
| BIOPORTO DIAGNOSTICS A/S | Tuborg Havnevej 15, st, 2900 Hellerup | 28 | 1004753299 |
Purpose
Selskabets formål er at drive forskning, handel, fabrikation og dermed beslægtet virksomhed primært inden for sundhedssektoren.
The purpose is quoted from the register in Danish.
Changes year by year
91 registered events12015
02016
02017
02018
12019
02020
42021
142022
82023
72024
82025
32026
20263 changesaccounts 1 · management 2
- AccountsAnnual report for 2025 published
- ManagementKlaus Juhl Wulff appointed board member
- ManagementNiels Jørgen Høy Nielsen stepped down as board member
20258 changesmanagement 6 · accounts 1 · industry 1
- ManagementCarsten Buhl appointed ceo
- ManagementCarsten Buhl appointed board member
- ManagementPeter Mørch Eriksen stepped down as board member
- ManagementPeter Mørch Eriksen stepped down as ceo
- AccountsAnnual report for 2024 published
- ManagementNiels Jørgen Høy Nielsen appointed board member
- ManagementNis Glavind Kruse stepped down as board member
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20247 changesaccounts 1 · management 6
- AccountsAnnual report for 2023 published
- ManagementGry Louise Husby Larsen appointed chair of the board
- ManagementPeter Mørch Eriksen appointed board member
- ManagementPeter Mørch Eriksen stepped down as chair of the board
- ManagementPeter Mørch Eriksen appointed ceo
- ManagementAnthony Paul Pare stepped down as ceo
- ManagementAnthony Paul Pare stepped down as board member
20238 changesmanagement 7 · accounts 1
- ManagementNis Glavind Kruse appointed board member
- ManagementPeter Mørch Eriksen appointed chair of the board
- ManagementJan Leth Christensen stepped down as chair of the board
- ManagementPeter Mørch Eriksen stepped down as board member
- ManagementJan Leth Christensen appointed chair of the board
- ManagementNeil Allan Goldman stepped down as chair of the board
- ManagementJan Leth Christensen stepped down as board member
- AccountsAnnual report for 2022 published
202214 changesmanagement 13 · accounts 1
- ManagementJan Leth Christensen appointed board member
- ManagementPeter Mørch Eriksen appointed board member
- ManagementJohn Patrick McDonough stepped down as board member
- ManagementJohn Patrick McDonough appointed board member
- ManagementHenrik Clausen stepped down as deputy chair
- AccountsAnnual report for 2021 published
- ManagementHenrik Clausen appointed deputy chair
- ManagementNeil Allan Goldman appointed chair of the board
- ManagementAnthony Paul Pare appointed ceo
- ManagementAnthony Paul Pare appointed board member
- ManagementPeter Mørch Eriksen stepped down as ceo
- ManagementPeter Mørch Eriksen stepped down as board member
- ManagementThomas Magnussen stepped down as chair of the board
- ManagementHenrik Clausen stepped down as board member
20214 changesaccounts 1 · management 3
- AccountsAnnual report for 2020 published
- ManagementHenrik Clausen appointed board member
- ManagementOle Larsen stepped down as board member
- ManagementTorben Arnth Nielsen stepped down as board member
20191 changemanagement 1
- ManagementOle Larsen appointed board member
20151 changemanagement 1
- ManagementOtto Christian Aagaard Rasmussen stepped down as chief financial officer
20142 changesaddress 1 · management 1
- AddressMoved to Tuborg Havnevej 15, st, 2900 Hellerup
- ManagementOtto Christian Aagaard Rasmussen appointed chief financial officer
20138 changesmanagement 8
- ManagementPeter Mørch Eriksen appointed ceo
- ManagementPeter Mørch Eriksen appointed board member
- ManagementThea Olesen stepped down as ceo
- ManagementThea Olesen stepped down as board member
- ManagementTorben Arnth Nielsen appointed board member
- ManagementLars Otto Uttenthal stepped down as board member
- ManagementThomas Magnussen appointed chair of the board
- ManagementKnud Carsten Bernhard Lønfeldt stepped down as chair of the board
20082 changesname 1 · industry 1
- NameName changed from ANTIBODYSHOP A/S to BIOPORTO DIAGNOSTICS A/S
- IndustryIndustry changed to Forskning og eksperimentel udvikling indenfor bioteknologi (721100)
20073 changesmanagement 3
- ManagementKnud Carsten Bernhard Lønfeldt appointed chair of the board
- ManagementLars Heslet stepped down as board member
- ManagementChristian Foldberg Rovsing stepped down as chair of the board
20062 changesmanagement 2
- ManagementThea Olesen appointed ceo
- ManagementEske Rygaard-Hjalsted stepped down as ceo
20057 changesmanagement 7
- ManagementLars Otto Uttenthal appointed board member
- ManagementThea Olesen appointed board member
- ManagementHenrik Lasse Lindblad stepped down as board member
- ManagementLars Heslet appointed board member
- ManagementClaus Henrik Jepsen stepped down as board member
- ManagementEske Rygaard-Hjalsted appointed ceo
- ManagementHenrik Lasse Lindblad stepped down as director
20042 changescapital 1 · ownership 1
- CapitalShare capital changed from 3,500,000 DKK to 4,750,000 DKK
- OwnershipBIOPORTO A/S registered as owner (100%)
20032 changesaddress 2
- AddressMoved to Grusbakken 6-8, 2820 Gentofte
- AddressMoved to Artillerivej 5, 2300 København S
20028 changesname 1 · capital 1 · management 6
- NameName changed from IMMUNOLEX ApS to ANTIBODYSHOP A/S
- CapitalShare capital changed from 213,000 DKK to 3,500,000 DKK
- ManagementHenrik Lasse Lindblad appointed board member
- ManagementChristian Foldberg Rovsing appointed director
- ManagementChristian Foldberg Rovsing stepped down as director
- ManagementChristian Foldberg Rovsing appointed chair of the board
- ManagementHenrik Lasse Lindblad appointed director
- ManagementClaus Henrik Jepsen appointed board member
20001 changename 1
- NameName changed from IDEGO ApS to IMMUNOLEX ApS
19991 changecapital 1
- CapitalShare capital changed from 200,000 DKK to 213,000 DKK
19982 changesname 1 · management 1
- NameName changed from RØNNEVANGSCENTRET ApS to IDEGO ApS
- ManagementTorsten Bjørn stepped down as director
19963 changesname 1 · management 2
- NameName changed from SCSK 1868 ApS to RØNNEVANGSCENTRET ApS
- ManagementTorsten Bjørn appointed director
- ManagementSteen Schierbeck stepped down as director
19952 changesfounded 1 · management 1
- FoundedRegistered as SCSK 1868 ApS
- ManagementSteen Schierbeck appointed director
Related companies
Same industry in Gentofte
- Pharmaceutical Research Associates Denmark ApS50 employees
- Novo Nordisk Clinical Innovation Centre A/S32 employees
- NIVI Development A/S9 employees
- Bioporto A/S8 employees
- Protein Frontiers ApS4 employees
- Aetas Labs ApS4 employees
Same people in management
- AL Sydbank A/Svia Torben Arnth Nielsen
- Coloplast A/Svia Knud Carsten Bernhard Lønfeldt
- GN Hearing A/Svia Carsten Buhl
- Bavarian Nordic A/Svia Ole Larsen
- Danfoss Power Solutions ApSvia Carl Edvard Gudbergsen
- Alk-abelló A/Svia Knud Carsten Bernhard Lønfeldt
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026.